scholarly journals Dopamine 2 and Somatostatin 1-5 Receptors Coexpression in Clinically Non-Functioning Pituitary Adenomas

2015 ◽  
pp. 369-377 ◽  
Author(s):  
F. GABALEC ◽  
M. DRASTIKOVA ◽  
T. CESAK ◽  
D. NETUKA ◽  
V. MASOPUST ◽  
...  
Keyword(s):  
Pituitary Adenomas ◽  
Somatostatin Receptors ◽  
High Expression ◽  
Quantitative Real Time Pcr ◽  
Null Cell ◽  
Expression Ratio ◽  
Adenoma Tissue ◽  
Dopamine 2 Receptor ◽  
Corticotroph Adenomas ◽  
Non Functioning Pituitary Adenomas

This study investigated quantitated expression of dopamine 2 receptor (D2R) and somatostatin receptors of the five types (SSTR1-SSTR5) in a large series of clinically non-functioning pituitary adenomas (CNFAs). Co-expression of these receptors in individual adenomas was studied as well as correlation between receptor types. Adenoma tissue from 198 patients who underwent surgery for CNFAs was analyzed by immunohistochemistry and quantitative real-time PCR. D2R and SSTR1-3 mRNA was expressed in all 198 adenomas. SSTR4 and SSTR5 were detectable in 85 % and 61 % of adenomas, respectively. Expression of D2R was significantly higher than that of the somatostatin receptors. The median relative expressions were as follows from highest D2R >> SSTR3 > SSTR2 > SSTR1 > SSTR5 > SSTR4. High relative expression (ratio to β-glucuronidase mRNA > 1) of D2R was found in 60 % of tumors, high expression of SSTR1 in 7.5 %, SSTR2 in 7 %, SSTR3 in 4 % and SSTR5 in 0.5 %. The quantity of D2R correlated positively with expression of SSTR2 and SSTR3, and negatively with SSTR1 and SSTR5. Among histological adenoma types, SSTR1 was significantly higher in null-cell adenomas and SSTR3 was lower in silent corticotroph adenomas. In conclusions, in CNFAs, high expression of somatostatin receptors is much less common than that of D2R, and co-expression of both these receptors is exceptional. D2R and SSTR3 seem to be the most promising targets for pharmacological treatment.

scholarly journals MON-467 Expression of Somatostatin Receptors in Aggressive Non-Functioning Pituitary Adenomas

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Alfonso Soto ◽  
Eva Venegas-Moreno ◽  
Noelia Gros Herguido ◽  
Elena Dios ◽  
Alvaro Flores-Martínez ◽  
...  
Keyword(s):  
Pituitary Adenomas ◽  
Somatostatin Receptors ◽  
Non Functioning Pituitary Adenomas

Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas

Pituitary ◽  
2011 ◽  
Vol 15 (2) ◽  
pp. 222-226 ◽  
Author(s):  
Filip Gabalec ◽  
Martin Beranek ◽  
David Netuka ◽  
Vaclav Masopust ◽  
Jiri Nahlovsky ◽  
...  
Keyword(s):  
Pituitary Adenomas ◽  
Receptor Expression ◽  
Dopamine 2 Receptor ◽  
Non Functioning Pituitary Adenomas

The corellation between somatostatin receptors expression and octreotide treatment in non-functioning pituitary adenomas

2016 ◽  
Vol 62 (5) ◽  
pp. 69
Author(s):  
Natalia Bozena Zawada
Keyword(s):  
Pituitary Adenomas ◽  
Tumour Size ◽  
Somatostatin Receptors ◽  
Somatostatin Analogues ◽  
Strong Expression ◽  
Tumour Shrinkage ◽  
Octreotide Treatment ◽  
Control Magnetic Resonance Imaging ◽  
Positive Results ◽  
Non Functioning Pituitary Adenomas

Introduction. Neurosurgery, which is the treatment of choice of non-functioning pituitary adenomas (NFPA), is often incurative. It usually leaves tumour residue that can regrow in the future. There is no established management for the postoperative period of NFPA, however, some data suggest that somatostatin analogues (SSA) can be effective, especially regarding somatostatin receptors (SSTR) presence in NFPA. SSTR scintigraphy and immunohistochemistry are used to assess SSTR expression in NFPA.Aim: to analyse the outcome of SSA treatment in NFPA and to correlate it with the results of SSTR scintigraphy and immunohistochemistry.Material and methods. Twenty six NFPA patients after incomplete neurosurgery with positive results of scintigraphy and immunohistochemistry were included in the study. All patients were treated with octreotide LAR 20mg intramuscular every 4 weeks. The tumour size was evaluated in control magnetic resonance imaging after 2 years of SSA therapy.Results. Tumour size remained stable in the majority of NFPA. Adenoma size reduction was observed in 2 patients with strong expression of SSTR2 in both scintigraphy and immunohistochemistry. Increase of tumour size was noticed in 4 patients whose tumours were characterised not only by the presence of SSTR2 and SSTR5 but also by strong expression of SSTR1 in immunohistochemistry.Conclusions. Only strong expression of SSTR2 can predict patients response to SSA treatment in NFPA. However, strong expression of SSTR1 observed in some of NFPA gives hope that introduction of new broad spectrum SSA like pasireotide would be more effective, especially in tumour shrinkage.

Oncocytic Transformation in Pituitary Adenomas: Immunohistochemical Analyses of 65 Cases

2004 ◽  
Vol 128 (7) ◽  
pp. 776-780
Author(s):  
María Niveiro ◽  
Francisco Ignacio Aranda ◽  
Artemio Payá ◽  
Evangelina Boix ◽  
Gloria Peiró ◽  
...  
Keyword(s):  
Pituitary Adenomas ◽  
Proliferative Activity ◽  
Older Patients ◽  
Null Cell ◽  
Ki 67 ◽  
Antimitochondrial Antibody ◽  
Clinicopathologic Factors ◽  
Pattern Versus ◽  
Corticotroph Adenomas ◽  
Immunohistochemical Analyses

Abstract Context.—Oncocytic change in pituitary adenomas has been evaluated by electron microscopy and more recently by immunohistochemistry. The clinical significance of this change is not well known, although some reports suggest a relationship with more aggressive behavior. Objective.—To assess the frequency of oncocytic change in pituitary adenomas and to correlate this finding with clinicopathologic factors. Design.—We studied oncocytic change in a series of 65 pituitary adenomas by immunohistochemistry. According to the percentage of oncocytic cells stained by antimitochondrial antibody, adenomas were classified in 3 groups: 50% or more, 10% to 49%, and 1% to 9% of oncocytic cells. Results.—Eight cases (12.3%) showing at least 50% of oncocytic cells were classified as oncocytic adenomas: 6 were gonadotroph adenomas and 2 were null-cell adenomas. Among the remaining cases, 9 (14%; all gonadotroph adenomas) showed 10% to 49% oncocytic cells, and in 14 cases (21.5%; 5 gonadotroph adenomas, 6 somatotroph adenomas, 2 corticotroph adenomas, and 1 thyrotroph adenoma) between 1% and 9% were shown. Patients with adenomas that showed oncocytic change presented more frequently at a higher average age (P = .05), but no relationship with extrasellar extension or proliferative activity measured by Ki-67 was observed. In somatotroph adenomas, cases with oncocytic change showed higher percentages of Ki-67 (P = .05) but no correlation with extrasellar extension or cytokeratin staining (dot pattern versus perinuclear) was found. Conclusion.—Adenomas with oncocytic change present more frequently in older patients, but they are not clinically more aggressive. In addition, somatotroph adenomas with oncocytic cells show similar cytokeratin pattern and higher proliferative activity, which is not correlated with local aggressiveness.

Sign in / Sign up

Export Citation Format

Share Document